We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Luca Licata
Feb 23, 2018
Why did she receive capecitabine and not palbociclib with fulvestrant? I would consider this combination
Martin Guerrero
Feb 27, 2018
Well that is not a proven combination. The combination with fulvestrant is with abemaciclib. In my opinion i believe she would have been a candidate to bilateral lymphadenectomy and fulvestrant only or in case she rejected surgery fulvestrant only
Juan Bares
Mar 02, 2018
Paloma 3 (The Lancet Oncology2016) is Palbociclib with Fulvestrant.
Luca Licata
Mar 02, 2018
In US and Europe palbocicllib is approved in combination with an aromatase inhibitor as initial endocrine based therapy and with fulvestrant for progressive disease following endocrine therapy.
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549978.htm
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/09/news_detail_002604.jsp&mid=WC0b01ac058004d5c1
If the patient received fulvestrant alone, she would be deprived of the possibility to do palbociclib thereafter...
May 08, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Sameer
Nasir
MD
Luca Licata
Feb 23, 2018
Martin Guerrero
Feb 27, 2018
Juan Bares
Mar 02, 2018
Luca Licata
Mar 02, 2018
May 08, 2024
Pending Moderator approval.